Samir Parekh, MD
The perception of multiple myeloma is changing, as researchers have discovered that what was once thought of as one disease is actually quite heterogenic, adding a greater need for genomic testing, explained Samir Parekh, MBBS.
“We are moving from an era where we looked at myeloma under the microscope and thought of it as one disease. With these resolution techniques like next-generation sequencing, we are able to understand the genomics better. We have found most patients have 4 or 5 different clones of disease that all behave differently with chemotherapy and need to be tracked to understand how to treat patients better,” said Parekh, an associate professor of medicine, hematology and medical oncology at the Icahn School of Medicine at Mount Sinai Hospital.
“In the future, every patient should have the tumor examined with genomics, in addition to having the pathology examined under a microscope,” added Parekh.
... to read the full story